Your browser doesn't support javascript.
loading
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review.
Uyttebroek, Saartje; Chen, Baixing; Onsea, Jolien; Ruythooren, Fred; Debaveye, Yves; Devolder, David; Spriet, Isabel; Depypere, Melissa; Wagemans, Jeroen; Lavigne, Rob; Pirnay, Jean-Paul; Merabishvili, Maya; De Munter, Paul; Peetermans, Willy E; Dupont, Lieven; Van Gerven, Laura; Metsemakers, Willem-Jan.
Afiliação
  • Uyttebroek S; Department of Otorhinolaryngology, UZ Leuven, Leuven, Belgium; Experimental Otorhinolaryngology, Rhinology Research, Department of Neurosciences, KU Leuven, Leuven, Belgium.
  • Chen B; Department of Trauma Surgery, UZ Leuven, Leuven, Belgium; Locomotor and Neurological Disorders, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
  • Onsea J; Department of Trauma Surgery, UZ Leuven, Leuven, Belgium; Locomotor and Neurological Disorders, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
  • Ruythooren F; Department of Trauma Surgery, UZ Leuven, Leuven, Belgium.
  • Debaveye Y; Department of Intensive Care Medicine, UZ Leuven, Leuven, Belgium; Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Devolder D; Pharmacy Department, UZ Leuven, Leuven, Belgium.
  • Spriet I; Pharmacy Department, UZ Leuven, Leuven, Belgium; Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Depypere M; Department of Laboratory Medicine, UZ Leuven, Leuven, Belgium; Laboratory of Clinical Bacteriology and Mycology, KU Leuven, Leuven, Belgium.
  • Wagemans J; Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Leuven, Belgium.
  • Lavigne R; Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Leuven, Belgium.
  • Pirnay JP; Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Neder-over-Heembeek, Belgium.
  • Merabishvili M; Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Neder-over-Heembeek, Belgium.
  • De Munter P; Department of General Internal Medicine, UZ Leuven, Leuven, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
  • Peetermans WE; Department of General Internal Medicine, UZ Leuven, Leuven, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
  • Dupont L; Department of Pneumology, UZ Leuven, Leuven, Belgium; Respiratory Diseases and Thoracic Surgery, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
  • Van Gerven L; Department of Otorhinolaryngology, UZ Leuven, Leuven, Belgium; Experimental Otorhinolaryngology, Rhinology Research, Department of Neurosciences, KU Leuven, Leuven, Belgium; Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.
  • Metsemakers WJ; Department of Trauma Surgery, UZ Leuven, Leuven, Belgium; Locomotor and Neurological Disorders, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. Electronic address: willem-jan.metsemakers@uzleuven.be.
Lancet Infect Dis ; 22(8): e208-e220, 2022 08.
Article em En | MEDLINE | ID: mdl-35248167
According to the latest reports from WHO, the incidence of antibiotic-resistant bacterial infections is increasing worldwide, resulting in increased morbidity and mortality and a rising pressure on health-care systems. However, the development of new antibiotics is an expensive and time-consuming process, urging scientists to seek alternative antimicrobial strategies. Over the past few decades, the concept of therapeutic administration of bacteriophages (also known as phages) has gained popularity worldwide. Although conceptually promising, the widespread implementation of phage therapy in routine clinical practice is restricted by the scarcity of safety and efficacy data obtained according to the strict standards of the applicable clinical trial regulations. In this systematic review, we list clinical data published between Jan 1, 2000 and Aug 14, 2021 on the safety and efficacy of phage therapy for difficult-to-treat bacterial infections, and provide an overview of trials and case studies on the use of phage therapy in several medical disciplines.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções Bacterianas / Bacteriófagos / Terapia por Fagos Tipo de estudo: Guideline / Systematic_reviews Limite: Humans Idioma: En Revista: Lancet Infect Dis Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções Bacterianas / Bacteriófagos / Terapia por Fagos Tipo de estudo: Guideline / Systematic_reviews Limite: Humans Idioma: En Revista: Lancet Infect Dis Ano de publicação: 2022 Tipo de documento: Article